Daiichi Sankyo Co Ltd (fra:D4S) Share Price

Company Profile

Business description
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.
Contact
3-5-1, Nihonbashi-honcho
Chuo-ku
Tokyo103-8426
JPN
T: +81 362251111
https://www.daiichisankyo.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2025
Employees
18,726

Recommended

After a historic rally in 2024, what lies ahead for this overvalued banking titan?

Simonelle Mody | 13 March 2025

The global education services provider has gone from stock market darling to one of the ASX's weakest performers. What gives?

Joseph Taylor | 12 March 2025

After the recent selloff, the bull market’s most in-demand stocks look much cheaper.

Sarah Hansen | 12 March 2025

Index	Last price	Change	% Change
All Ordinaries	8,013.30	46.70	0.59%
CAC 40	7,938.21	50.75	-0.64%
DAX 40	22,567.14	109.27	-0.48%
Dow JONES (US)	40,813.57	537.36	-1.30%
FTSE 100	8,542.56	1.59	0.02%
HKSE	24,039.04	576.39	2.46%
NASDAQ	17,303.01	345.44	-1.96%
Nikkei 225	37,053.10	263.07	0.72%
NZX 50 Index	12,266.25	57.20	0.47%
S&P 500	5,521.52	77.78	-1.39%
S&P/ASX 200	7,789.70	40.60	0.52%
SSE Composite Index	3,418.05	59.32	1.77%